A new article from Patient Power highlights findings from a paper authored by Ovarian Cancer Research Alliance (OCRA) and Komodo Health, that reveals significant gaps in genetic testing for ovarian cancer patients.
Chad Ramsey, OCRA’s Vice President of Policy, spoke with Patient Power about the study’s results and the urgent need to close these gaps. Genetic and biomarker testing are critical tools that not only guide treatment decisions but also help identify hereditary cancer risk in families — yet too many patients are not receiving the testing recommended by national guidelines.
Read “Too Many Ovarian Cancer Patients Missing Out on Life-Changing Genetic Testing,” by Hailey Hudson for Patient Power
